Dr. Paul Meyers and the pediatric oncology team at @sloan_kettering presented a case study of our investigational product candidate TK216 in a patient with Ewing Sarcoma at the Fall Children’s Oncology Group Meeting. Read the announcement here: bit.ly/2mnBJcb

This week, our President and CEO Jim Breitmeyer spoke with WuXi AppTec about our investigational product candidate in clinical trials to treat patients with Ewing Sarcoma and the challenging field of #pediatriccancer bit.ly/2kovQLb

In honor of #WorldCancerResearchDay today, we would like to share our commitment in pioneering innovative areas of cancer research to create new treatments for patients with critical unmet medical needs!

In case you missed it: Nasdaq hosted Oncternal’s CEO Jim Breitmeyer on their San Diego #biotech edition of the Nasdaq Spotlight Series in July! Thank you Nasdaq and @Ivonne_romeo #NasdaqSpotlight

Today we announced an additional complete response in a MCL patient treated with cirmtuzumab + ibrutinib. We also opened enrollment of the Phase 1b expansion cohort of our MCL clinical trial. This follows our interim data at the ASCO meeting in June! bit.ly/2oglcbh

We’re excited to kick-off a new series on #PediatricCancer that highlights companies seeking novel therapies for children, a long-standing challenge. Very thankful to @Oncternal CEO James Breitmeyer for sharing his thoughts with us. #InnovationThatMatters bit.ly/WXAT-Oncternal

Encouraging progress for two #cirm supported trials conducted by Capricor Therapeutics and Oncternal Therapeutics #DuchenneMuscularDystrophy #lymphoma bit.ly/35vXuZx

Our CEO Jim Breitmeyer spoke with the WallStreetTranscript on his journey at Oncternal and our innovative pipeline of cancer product candidates. Read the feature here: bit.ly/32KOX2W

We announced our Q3 financial results and provided an update on the opening of a Ph2 study of Cirmtuzumab in combination with ibrutinib in patients with CLL and a Ph1b expansion cohort in patients with MCL. Join us for a live webcast at 2:00 p.m. PT bit.ly/2WT27bW

We are proud to be able to share our innovative company story, diverse pipeline of potentially first-in-class product candidates and collaboration with California Institute for Regenerative Medicine at the SDIC Meeting!

Dr. Hun Ju Lee, MD, spoke with Targeted Oncology about our Phase Ib clinical study of Cirmtuzumab in combination with ibrutinib, which now includes an expansion cohort in patients with mantle cell lymphoma. Check out the full interview here: bit.ly/36TrSh3

This week we presented interim clinical data from our Phase 1 trial of TK216 in Ewing Sarcoma at the CTOS 2019 Annual Meeting. We are encouraged by the early activity and look forward to continuing the momentum #CTOS2019 oncternal.peek.link/938

We will be presenting at the Stifel Healthcare Conference today at 4:10 p.m. ET. Check out the live webcast on our website here: oncternal.peek.link/96S

We are looking forward to attending the 31st Annual @PiperJaffrayCo Healthcare Conference this year! Check out our President and CEO Jim Breitmeyer presenting a company overview on Thursday, December 5 at 11:50 a.m. ET oncternal.peek.link/99o

Honoring the living legend David Hale tonight as our 2019 Connect Hall of Fame inductee. Thank you for being a co-founder of Connect and a champion of entrepreneurship and San Diego! #InnovationAwards #ConnectSD

Congratulations to our Chairman David Hale on being inducted into the Connect Entrepreneur Hall of Fame at last night’s 2019 #InnovationAwards!

We are proud to have been part of the ASH 2019 Meeting where a clinical data update was presented on our investigational product candidate cirmtuzumab in combination with ibrutinib. In case you missed us, learn more on our website! #ASH2019 oncternal.peek.link/9wQ

The ASH 2019 Meeting featured the promising results of four #CIRM funded clinical trials conducted by @FortySevenInc Sangamo Therapeutics Oncternal Therapeutics and Rocket Pharmaceuticals bit.ly/36nuBy0

We announced the enrollment opening for a Ph1b clinical trial expansion cohort of our investigational product candidate TK216 in Ewing sarcoma patients following favorable interim results & continuing our mission to develop novel therapies for #RareDisease bit.ly/2YDbu0c

We presented interim data from the ongoing, investigator-sponsored Ph1b clinical study of our investigational product candidate, cirmtuzumab, at the SABCS Breast Cancer Symposium. Check out our presentation and release on our website! #SABCS19 oncternal.peek.link/9Aq